Labetuzumab anti-DTPA-indium bispecific monoclonal antibody

N/A

Report date: 2025/12/01 17:16:54

Base Information

Drug NameLabetuzumab anti-DTPA-indium bispecific monoclonal antibody

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody diagnosticsDiagnostic agent (In vivo) > Radionuclide Imaging agent +[6]

Mechanisms of ActionRadionuclide imaging enhancers

TargetsNot applicable

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPending (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesImmunomedics Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesImmunomedics Inc

Active IndicationsN/A

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A